News & Updates

QI initiative reduces time to administer biologics, ER visits in IBD

13 Mar 2022

A quality improvement (QI) intervention is associated with reduced medication administration times for biologic therapy by fast-tracking provider-dependent steps and with fewer emergency room (ER) visits, reveals a recent study.

QI initiative reduces time to administer biologics, ER visits in IBD

13 Mar 2022

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

12 Mar 2022 by

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

12 Mar 2022

Endovascular therapy has added value in patients with acute large vessel occlusion

11 Mar 2022 by

Endovascular therapy (EVT) in addition to medical therapy appeared to improve outcomes in patients with acute large vessel occlusion (LVO) with large ischaemic core following a stroke, according to results of the RESCUE-Japan LIMIT* trial.

Endovascular therapy has added value in patients with acute large vessel occlusion

11 Mar 2022

Which melphalan formulation works better against engraftment syndrome?

11 Mar 2022

The incidence of engraftment syndrome (ES), a common complication of autologous haematopoietic cell transplantation (HCT), is comparable between melphalan formulations among patients with multiple myeloma and immunoglobulin light chain amyloidosis, reveals a study.

Which melphalan formulation works better against engraftment syndrome?

11 Mar 2022

Obinutuzumab + SoC improves renal responses in LN patients

11 Mar 2022 by

The addition of obinutuzumab, a humanized type II anti-CD20 monoclonal antibody that induces potent B-cell depletion, to a background of standard-of-care (SoC) therapy led to improved renal responses in patients with proliferative lupus nephritis (LN) compared with SoC alone, findings from the phase II NOBILITY trial have shown.

Obinutuzumab + SoC improves renal responses in LN patients

11 Mar 2022

Shorter antibiotic regimen enough in kids with pneumonia?

10 Mar 2022 by

Children with non-severe community-acquired pneumonia (CAP) may benefit from a 5-day antibiotic regimen compared with the current standard regimen of 10 days, according to results of the US-based SCOUT-CAP trial.

Shorter antibiotic regimen enough in kids with pneumonia?

10 Mar 2022

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

10 Mar 2022 by

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

10 Mar 2022

Delamanid-based regimens work against multidrug-resistant tuberculosis

10 Mar 2022

The use of delamanid-containing regimens is safe and effective in the management of multidrug-resistant tuberculosis (MDR-TB), with high culture conversion and treatment success rates despite extensive resistance patterns, according to the results of a meta-analysis.

Delamanid-based regimens work against multidrug-resistant tuberculosis

10 Mar 2022

Magnesium supplementation confers no cardiovascular benefit

10 Mar 2022

Supplementation with oral magnesium for 24 weeks hardly produces any change in arterial stiffness or blood pressure (BP), as do magnesium oxide and magnesium sulphate, as shown in a study.

Magnesium supplementation confers no cardiovascular benefit

10 Mar 2022

Continuing enzalutamide after progression improves PFS in mCRPC

09 Mar 2022 by

In patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression while on enzalutamide treatment, continuing enzalutamide appears to improve progression-free survival (PFS), according to results of the phase IIIb PRESIDE trial.

Continuing enzalutamide after progression improves PFS in mCRPC

09 Mar 2022

News & Updates

Filter by Specialty:

Specialty:

QI initiative reduces time to administer biologics, ER visits in IBD

QI initiative reduces time to administer biologics, ER visits in IBD

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

KEYNOTE-590 extended follow-up shows pembro + chemo maintains survival in advanced oesophageal cancer

Endovascular therapy has added value in patients with acute large vessel occlusion

Endovascular therapy has added value in patients with acute large vessel occlusion

Which melphalan formulation works better against engraftment syndrome?

Which melphalan formulation works better against engraftment syndrome?

Obinutuzumab + SoC improves renal responses in LN patients

Obinutuzumab + SoC improves renal responses in LN patients

Shorter antibiotic regimen enough in kids with pneumonia?

Shorter antibiotic regimen enough in kids with pneumonia?

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

OS benefit of NIVO + IPI holds out through 5 years over sunitinib in sarcomatoid RCC

Delamanid-based regimens work against multidrug-resistant tuberculosis

Delamanid-based regimens work against multidrug-resistant tuberculosis

Magnesium supplementation confers no cardiovascular benefit

Magnesium supplementation confers no cardiovascular benefit

Continuing enzalutamide after progression improves PFS in mCRPC

Continuing enzalutamide after progression improves PFS in mCRPC